Estudo randomizado | Everolimo não é benéfico quando adicionado à terapia endócrina adjuvante para pacientes com câncer de mama primário positivo para receptor de hormônio de alto risco e negativo para receptor 2 do fator de crescimento epidérmico humano.

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer – Journal of Clinical Oncology

Comentários no Twitter

Previously presented @myESMO VP, the #UNIRAD RCT of adjuvant everolimus in high-risk EBC is now published on @JCO_ASCO. Trial stopped for futility: everolimus didn’t improve DFS & was poorly tolerated. Large research effort answering an important question.https://t.co/wmYLWpDWTC

— Paolo Tarantino (@PTarantinoMD) May 24, 2022

Everolimus added to adjuvant ET fails to improve DFS in patients with high-risk HR+ve, HER2 neg primary breast cancer; poorly tolerated -53.4% discontinuation ratehttps://t.co/lmq2jhbhCO

— K Pavithran (@drkpavithran) May 24, 2022